Pregled bibliografske jedinice broj: 1073694
Does Normal Diluted Russell Viper Venom Time Test Result Can Exclude Concentrations of Direct Oral Anticoagulants below 30 ng/mL?
Does Normal Diluted Russell Viper Venom Time Test Result Can Exclude Concentrations of Direct Oral Anticoagulants below 30 ng/mL? // Res Pract Thromb Haemost / Cushman, Mary (ur.).
Medford: John Wiley & Sons, 2020. PB0551, 1 (poster, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 1073694 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Does Normal Diluted Russell Viper Venom Time
Test Result Can Exclude Concentrations of
Direct Oral Anticoagulants below 30 ng/mL?
Autori
Margetić, Sandra ; Ćelap, Ivana ; Mihić, Roman ; Šupraha Goreta, Sandra.
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Res Pract Thromb Haemost
/ Cushman, Mary - Medford : John Wiley & Sons, 2020
Skup
Annual Meeting of the International Society on Thrombosis and Haemostasis (ISTH 2020)
Mjesto i datum
Online, 12.07.2020. - 14.07.2020
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
Direct Oral Anticoagulants, lupus anticoagulant
Sažetak
Background: Direct oral anticoagulants (DOACs), i.e. dabigatran, rivaroxaban and apixaban, have strong effect on dilute Russell viper venom screen (dRVVTs) and confirm (dRVVTc) test results. Therefore, it is possible to assume potential application of these assays in exclusion of DOACs presence in circulation. Aims: To investigate whether normal dRVVT test result expressed as calculated lupus anticoagulant (LA) ratio i.e., dRVVTs/dRVVTc, can exclude clinically relevant concentration (>30 ng/mL) of DOACs. Methods: DOACs concentrations were measured using commercial assays on BCS XP analyzer (Siemens Healthineers, Germany): Innovance heparin (Siemens Healthineers, Germany) calibrated with specific calibrators (Hyphen BioMed, France) for rivaroxaban and apixaban ; Innovance DTI assay (Siemens Healthineers, Germany) for dabigatran. LA ratio was calculated from measured dRVVTs and dRVVTc tests with commercial LA1 Screening and LA2 Confirmation reagents using original protocols (Siemens Healthineers, Germany). Differences between groups were tested using Kruskal-Wallis test. Receiver operating characteristics (ROC) analysis was performed for diagnostic accuracy estimation at cut-off value of 30 ng/mL for each DOACs. The study was funded by the Croatian Science Foundation as part of the research project IP- 2016-06-8208. Results: LA ratios showed significant differences between false positive (FP) and true negative (TN) LA results (P< 0.001) for all three DOACs (Table 1). Among patients with FP and TN results of LA, concentrations of DOACs were significantly different for rivaroxaban only (P< 0.001). ROC analysis confirmed that normal LA ratio result can´t exclude concentration below 30 ng/mL for dabigatran and apixaban (area under curve (AUC=0.625, P>0.05), whereas normal LA ratio could exclude rivaroxaban concentration below 30 ng/mL, AUC=0.967, P< 0.001 (Table 1). Conclusions: Based on the normal dRVVT result (LA ratio), it is not possible to exclude low concentration of dabigatran and apixaban. On the contrary, normal dRVVT (LA ratio) could be potentially useful for excluding low concentration of rivaroxaban.
Izvorni jezik
Hrvatski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
HRZZ-IP-2016-06-8208 - Novi oralni antikoagulansi: povezanost koncentracije lijeka i antikoagulantnog učinka (LAB-NOAC) (Margetić, Sandra, HRZZ - 2016-06) ( CroRIS)
Ustanove:
Farmaceutsko-biokemijski fakultet, Zagreb,
KBC "Sestre Milosrdnice"
Citiraj ovu publikaciju:
Časopis indeksira:
- Web of Science Core Collection (WoSCC)
- Emerging Sources Citation Index (ESCI)